Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

What Was Tested

The trial (phase 3) is built around Vasopressin.

The norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation only as a rescue strategy for hemodynamic management of critically ill patients with vasopressor dependent sepsis.

It had two arms (groups): Early Vasopressin (experimental) and Norepinephrine plus vasopressin for rescue (active comparator).

The registry classes the interventions as drug.

More on the Plan

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated body response to infection.

Its most severe form, septic shock, occurs when underlying circulatory and cellular metabolic abnormalities are pronounced, indicating greater severity and higher mortality.

Vasopressor use is a cornerstone aspect in the treatment of critically ill patients with sepsis-associated hemodynamic dysfunction, with norepinephrine, a catecholamine, being the vasopressor of choice.

Vasopressin is an endogenous peptide hormone with potential advantages over norepinephrine in a catecholamine-sparing strategy for treating sepsis-associated hemodynamic dysfunction.

Who Took Part

2800 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Patients with vasopressor dependent sepsis, defined by infection suspicion and antibiotic administration or laboratory confirmed viral infection, plus hypotension with the need of vasopressors for at least one hour;. Admitted or expected to be admitted to the ICU in the next 12 hours. Adequate volume resuscitation in the opinion of the attending physician.

The full record lists 4 inclusion and 9 exclusion criteria; among the exclusions: use of other vasopressors (except norepinephrine) at the moment of inclusion; use of vasopressors for sepsis in the last 7 days; suspected or confirmed acute mesenteric ischemia.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Being open-label, the Vasopressin study did not mask who received what.

It started in 2024-11-21 with completion listed for 2027-08.

It ran at 8 sites in Brazil (8).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: All-cause mortality or renal replacement therapy (time frame: 28 days).

It also tracked 8 secondary outcomes, for example All-cause mortality, Renal replacement-therapy, Renal replacement-free days, ICU-free days, Organ support-free days and its components and Cardiac arrhythmias.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Vasopressin in 2800 people.

With 2800 participants it is a large trial for this field.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Vasopressin compound page, all human trials.